Dr Ira Deveson
Dr Ira Deveson is a mid-career researcher with expertise in clinical genomics, biotechnology development & bioinformatics. He leads Garvan’s Genomic Technologies research lab, with a current focus on applications of long-read sequencing in clinical genomics. His work spans from computational methods development and software/hardware engineering, to large-scale genomic analysis of diverse cohorts in health and disease. Dr Ira Deveson graduated with a Bachelor of Philosophy from the Australian National University in 2012. He completed a PhD at the Garvan Institute of Medical Research from 2014-2017, supervised by Prof John Mattick and Dr Tim Mercer. Dr Deveson's PhD focused on genome/transcriptome research and bioinformatics, and earned him recognition with the JD Catcheside prize from the Genomics Society of Australasia. Dr Deveson was awarded an Early Career Fellowship from the Cancer Institute NSW (2018) and a prestigious NHMRC Investigator Grant (2020). He was appointed as Head of Garvan's Genomic Technologies Lab in 2020 and has since been awarded multiple significant MRFF grants to support his work on long-read sequencing technology development. In addition to his research role, Dr Deveson leads the Long-read Sequencing Team within Garvan’s Sequencing Platform.
- 2012University Medal for Biology - Australian National University: outstanding graduate from the biological sciences
- 2017DG Catcheside Prize - Genetics Society of Australasia: most outstanding Australasian PhD graduate in the field of genetics
- 2022Science advances10.1126/sciadv.abm5386
Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing.
- 2022Nature biotechnology10.1038/s41587-021-01147-4
Fast nanopore sequencing data analysis with SLOW5.
- 2020Nature communications10.1038/s41467-020-20075-6
Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis.
- 2021Nature biotechnology10.1038/s41587-021-00857-z
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology.
- 2016Nature methods10.1038/nmeth.3957
Representing genetic variation with synthetic DNA standards.